DOCSLIB.ORG

V3.23 Durable Medical Equipment, Supplies, Vision and Hearing Hardware Nationwide by HCPCS Code

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
V3.23 Durable Medical Equipment, Supplies, Vision and Hearing Hardware Nationwide by HCPCS Code TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE v3.23 (January - December 2018) PAGE 1 of 95 Status/ Usage HCPCS Code Modifier 1 HCPCS Code Description Charge GAAF Category Indicator 2 A0100 Blank NONEMERGENCY TRANSPORT TAXI Blank $20.81 HCPCS - Non-Drugs A0110 Blank NONEMERGENCY TRANSPORT BUS Blank $61.62 HCPCS - Non-Drugs A0120 Blank NONER TRANSPORT MINI-BUS Blank $183.09 HCPCS - Non-Drugs A0130 Blank NONER TRANSPORT WHEELCH VAN Blank $85.54 HCPCS - Non-Drugs A0140 Blank NONEMERGENCY TRANSPORT AIR Blank $1,211.38 HCPCS - Non-Drugs A0160 Blank NONER TRANSPORT CASE WORKER Blank $2.42 HCPCS - Non-Drugs A0170 Blank TRANSPORT PARKING FEES/TOLLS Blank $303.72 HCPCS - Non-Drugs A0180 Blank NONER TRANSPORT LODGNG RECIP Blank $809.69 HCPCS - Non-Drugs A0190 Blank NONER TRANSPORT MEALS RECIP Blank $181.99 HCPCS - Non-Drugs A0398 Blank ALS ROUTINE DISPOSBLE SUPPLS Blank $132.93 HCPCS - Non-Drugs A0422 Blank AMBULANCE 02 LIFE SUSTAINING Blank $126.28 HCPCS - Non-Drugs A4206 Blank 1 CC STERILE SYRINGE&NEEDLE Blank $0.94 HCPCS - Non-Drugs A4207 Blank 2 CC STERILE SYRINGE&NEEDLE Blank $0.94 HCPCS - Non-Drugs A4208 Blank 3 CC STERILE SYRINGE&NEEDLE Blank $0.94 HCPCS - Non-Drugs A4209 Blank 5+ CC STERILE SYRINGE&NEEDLE Blank $0.94 HCPCS - Non-Drugs A4210 Blank NONNEEDLE INJECTION DEVICE Blank $1,233.33 HCPCS - Non-Drugs A4211 Blank SUPP FOR SELF-ADM INJECTIONS Blank $57.07 HCPCS - Non-Drugs A4212 Blank NON CORING NEEDLE OR STYLET Blank $13.31 HCPCS - Non-Drugs A4213 Blank 20+ CC SYRINGE ONLY Blank $1.88 HCPCS - Non-Drugs A4215 Blank STERILE NEEDLE Blank $1.29 HCPCS - Non-Drugs A4216 Blank STERILE WATER/SALINE, 10 ML Blank $1.09 HCPCS - Non-Drugs A4217 Blank STERILE WATER/SALINE, 500 ML Blank $6.97 HCPCS - Non-Drugs A4217 AU STERILE WATER/SALINE, 500 ML Blank $6.97 HCPCS - Non-Drugs A4218 Blank STERILE SALINE OR WATER Blank $3.59 HCPCS - Non-Drugs A4220 Blank INFUSION PUMP REFILL KIT Blank $86.92 HCPCS - Non-Drugs A4221 Blank SUPP NON-INSULIN INF CATH/WK Blank $111.76 HCPCS - Non-Drugs A4222 Blank INFUSION SUPPLIES WITH PUMP Blank $144.04 HCPCS - Non-Drugs A4223 Blank INFUSION SUPPLIES W/O PUMP Blank $131.27 HCPCS - Non-Drugs A4224 Blank SUPPLY INSULIN INF CATH/WK Blank $111.76 HCPCS - Non-Drugs A4225 Blank SUP/EXT INSULIN INF PUMP SYR Blank $25.36 HCPCS - Non-Drugs A4230 Blank INFUS INSULIN PUMP NON NEEDL Blank $22.52 HCPCS - Non-Drugs A4231 Blank INFUSION INSULIN PUMP NEEDLE Blank $9.38 HCPCS - Non-Drugs A4232 Blank SYRINGE W/NEEDLE INSULIN 3CC Blank $5.80 HCPCS - Non-Drugs A4233 Blank ALKALIN BATT FOR GLUCOSE MON Blank $4.98 HCPCS - Non-Drugs A4233 NU ALKALIN BATT FOR GLUCOSE MON Blank $4.98 HCPCS - Non-Drugs A4234 Blank J-CELL BATT FOR GLUCOSE MON Blank $23.02 HCPCS - Non-Drugs A4234 NU J-CELL BATT FOR GLUCOSE MON Blank $23.02 HCPCS - Non-Drugs A4235 Blank LITHIUM BATT FOR GLUCOSE MON Blank $9.76 HCPCS - Non-Drugs A4235 NU LITHIUM BATT FOR GLUCOSE MON Blank $9.76 HCPCS - Non-Drugs A4236 Blank SILVR OXIDE BATT GLUCOSE MON Blank $11.32 HCPCS - Non-Drugs A4236 NU SILVR OXIDE BATT GLUCOSE MON Blank $11.32 HCPCS - Non-Drugs A4244 Blank ALCOHOL OR PEROXIDE PER PINT Blank $1.88 HCPCS - Non-Drugs A4245 Blank ALCOHOL WIPES PER BOX Blank $5.45 HCPCS - Non-Drugs A4246 Blank BETADINE/PHISOHEX SOLUTION Blank $5.45 HCPCS - Non-Drugs A4247 Blank BETADINE/IODINE SWABS/WIPES Blank $7.59 HCPCS - Non-Drugs A4248 Blank CHLORHEXIDINE ANTISEPT Blank $5.40 HCPCS - Non-Drugs A4250 Blank URINE REAGENT STRIPS/TABLETS Blank $26.16 HCPCS - Non-Drugs A4252 Blank BLOOD KETONE TEST OR STRIP Blank $11.55 HCPCS - Non-Drugs A4253 Blank BLOOD GLUCOSE/REAGENT STRIPS Blank $113.18 HCPCS - Non-Drugs A4253 NU BLOOD GLUCOSE/REAGENT STRIPS Blank $113.18 HCPCS - Non-Drugs A4255 Blank GLUCOSE MONITOR PLATFORMS Blank $43.63 HCPCS - Non-Drugs A4256 Blank CALIBRATOR SOLUTION/CHIPS Blank $32.97 HCPCS - Non-Drugs A4256 KL CALIBRATOR SOLUTION/CHIPS Blank $28.96 HCPCS - Non-Drugs A4257 Blank REPLACE LENSSHIELD CARTRIDGE Blank $102.17 HCPCS - Non-Drugs A4258 Blank LANCET DEVICE EACH Blank $20.68 HCPCS - Non-Drugs A4258 KL LANCET DEVICE EACH Blank $17.89 HCPCS - Non-Drugs A4259 Blank LANCETS PER BOX Blank $13.85 HCPCS - Non-Drugs 1, 2 - See end of the table for notes regarding these fields. TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE v3.23 (January - December 2018) PAGE 2 of 95 Status/ Usage HCPCS Code Modifier 1 HCPCS Code Description Charge GAAF Category Indicator 2 A4259 KL LANCETS PER BOX Blank $12.13 HCPCS - Non-Drugs A4261 Blank CERVICAL CAP CONTRACEPTIVE Blank $77.88 HCPCS - Non-Drugs A4262 Blank TEMPORARY TEAR DUCT PLUG Blank $0.94 HCPCS - Non-Drugs A4263 Blank PERMANENT TEAR DUCT PLUG Blank $58.28 HCPCS - Non-Drugs A4264 Blank INTRATUBAL OCCLUSION DEVICE Blank $2,243.66 HCPCS - Non-Drugs A4265 Blank PARAFFIN Blank $37.05 HCPCS - Non-Drugs A4266 Blank DIAPHRAGM Blank $87.22 HCPCS - Non-Drugs A4267 Blank MALE CONDOM Blank $0.94 HCPCS - Non-Drugs A4268 Blank FEMALE CONDOM Blank $1.20 HCPCS - Non-Drugs A4269 Blank SPERMICIDE Blank $1.88 HCPCS - Non-Drugs A4270 Blank DISPOSABLE ENDOSCOPE SHEATH Blank $17.96 HCPCS - Non-Drugs A4280 Blank BRST PRSTHS ADHSV ATTCHMNT Blank $8.48 HCPCS - Non-Drugs A4281 Blank REPLACEMENT BREASTPUMP TUBE Blank $20.04 HCPCS - Non-Drugs A4282 Blank REPLACEMENT BREASTPUMP ADPT Blank $21.39 HCPCS - Non-Drugs A4283 Blank REPLACEMENT BREASTPUMP CAP Blank $116.11 HCPCS - Non-Drugs A4284 Blank REPLCMNT BREAST PUMP SHIELD Blank $26.16 HCPCS - Non-Drugs A4285 Blank REPLCMNT BREAST PUMP BOTTLE Blank $17.67 HCPCS - Non-Drugs A4286 Blank REPLCMNT BREASTPUMP LOK RING Blank $68.50 HCPCS - Non-Drugs A4290 Blank SACRAL NERVE STIM TEST LEAD Blank $703.49 HCPCS - Non-Drugs A4300 Blank CATH IMPL VASC ACCESS PORTAL Blank $40.41 HCPCS - Non-Drugs A4301 Blank IMPLANTABLE ACCESS SYST PERC Blank $19.73 HCPCS - Non-Drugs A4305 Blank DRUG DELIVERY SYSTEM >=50 ML Blank $19.73 HCPCS - Non-Drugs A4306 Blank DRUG DELIVERY SYSTEM <=50 ML Blank $26.87 HCPCS - Non-Drugs A4310 Blank INSERT TRAY W/O BAG/CATH Blank $15.90 HCPCS - Non-Drugs A4311 Blank CATHETER W/O BAG 2-WAY LATEX Blank $28.68 HCPCS - Non-Drugs A4312 Blank CATH W/O BAG 2-WAY SILICONE Blank $35.28 HCPCS - Non-Drugs A4313 Blank CATHETER W/BAG 3-WAY Blank $36.29 HCPCS - Non-Drugs A4314 Blank CATH W/DRAINAGE 2-WAY LATEX Blank $49.02 HCPCS - Non-Drugs A4315 Blank CATH W/DRAINAGE 2-WAY SILCNE Blank $51.24 HCPCS - Non-Drugs A4316 Blank CATH W/DRAINAGE 3-WAY Blank $55.32 HCPCS - Non-Drugs A4320 Blank IRRIGATION TRAY Blank $10.99 HCPCS - Non-Drugs A4321 Blank CATH THERAPEUTIC IRRIG AGENT Blank $10.00 HCPCS - Non-Drugs A4322 Blank IRRIGATION SYRINGE Blank $7.03 HCPCS - Non-Drugs A4326 Blank MALE EXTERNAL CATHETER Blank $21.44 HCPCS - Non-Drugs A4327 Blank FEM URINARY COLLECT DEV CUP Blank $87.51 HCPCS - Non-Drugs A4328 Blank FEM URINARY COLLECT POUCH Blank $21.09 HCPCS - Non-Drugs A4330 Blank STOOL COLLECTION POUCH Blank $14.54 HCPCS - Non-Drugs A4331 Blank EXTENSION DRAINAGE TUBING Blank $7.45 HCPCS - Non-Drugs A4332 Blank LUBE STERILE PACKET Blank $0.30 HCPCS - Non-Drugs A4333 Blank URINARY CATH ANCHOR DEVICE Blank $3.55 HCPCS - Non-Drugs A4334 Blank URINARY CATH LEG STRAP Blank $7.87 HCPCS - Non-Drugs A4335 Blank INCONTINENCE SUPPLY Blank $0.61 HCPCS - Non-Drugs A4336 Blank URETHRAL INSERT Blank $3.80 HCPCS - Non-Drugs A4338 Blank INDWELLING CATHETER LATEX Blank $24.51 HCPCS - Non-Drugs A4340 Blank INDWELLING CATHETER SPECIAL Blank $59.98 HCPCS - Non-Drugs A4344 Blank CATH INDW FOLEY 2 WAY SILICN Blank $31.41 HCPCS - Non-Drugs A4346 Blank CATH INDW FOLEY 3 WAY Blank $37.59 HCPCS - Non-Drugs A4349 Blank DISPOSABLE MALE EXTERNAL CAT Blank $5.16 HCPCS - Non-Drugs A4351 Blank STRAIGHT TIP URINE CATHETER Blank $4.53 HCPCS - Non-Drugs A4352 Blank COUDE TIP URINARY CATHETER Blank $13.25 HCPCS - Non-Drugs A4353 Blank INTERMITTENT URINARY CATH Blank $14.97 HCPCS - Non-Drugs A4354 Blank CATH INSERTION TRAY W/BAG Blank $23.63 HCPCS - Non-Drugs A4355 Blank BLADDER IRRIGATION TUBING Blank $18.60 HCPCS - Non-Drugs A4356 Blank EXT URETH CLMP OR COMPR DVC Blank $86.78 HCPCS - Non-Drugs A4357 Blank BEDSIDE DRAINAGE BAG Blank $19.52 HCPCS - Non-Drugs A4358 Blank URINARY LEG OR ABDOMEN BAG Blank $13.62 HCPCS - Non-Drugs A4360 Blank DISPOSABLE EXT URETHRAL DEV Blank $1.20 HCPCS - Non-Drugs 1, 2 - See end of the table for notes regarding these fields. TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE v3.23 (January - December 2018) PAGE 3 of 95 Status/ Usage HCPCS Code Modifier 1 HCPCS Code Description Charge GAAF Category Indicator 2 A4361 Blank OSTOMY FACE PLATE Blank $36.08 HCPCS - Non-Drugs A4362 Blank SOLID SKIN BARRIER Blank $7.66 HCPCS - Non-Drugs A4363 Blank OSTOMY CLAMP, REPLACEMENT Blank $5.64 HCPCS - Non-Drugs A4364 Blank ADHESIVE, LIQUID OR EQUAL Blank $4.45 HCPCS - Non-Drugs A4366 Blank OSTOMY VENT Blank $2.08 HCPCS - Non-Drugs A4367 Blank OSTOMY BELT Blank $15.02 HCPCS - Non-Drugs A4368 Blank OSTOMY FILTER Blank $0.65 HCPCS - Non-Drugs A4369 Blank SKIN BARRIER LIQUID PER OZ Blank $5.77 HCPCS - Non-Drugs A4371 Blank SKIN BARRIER POWDER PER OZ Blank $8.35 HCPCS - Non-Drugs A4372 Blank SKIN BARRIER SOLID 4X4 EQUIV Blank $9.45 HCPCS - Non-Drugs A4373 Blank SKIN BARRIER WITH FLANGE Blank $13.55 HCPCS - Non-Drugs A4375 Blank DRAINABLE PLASTIC PCH W FCPL Blank $35.07 HCPCS - Non-Drugs A4376 Blank DRAINABLE RUBBER PCH W FCPLT Blank $95.12 HCPCS - Non-Drugs A4377 Blank DRAINABLE PLSTIC PCH W/O FP Blank $9.65 HCPCS - Non-Drugs A4378 Blank DRAINABLE RUBBER PCH
Load more

Recommended publications
  • Drug Code List
    HCPCS/Drug Code List Version 13.2 Revised 6/1/21 List will be updated routinely Disclaimer: For drug codes that require an NDC, coverage depends on the drug NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service. Note: Physician/Facility-administered medications are reimbursed using the Centers for Medicare and Medicaid Services (CMS) Part B Drug pricing file found on the CMS website--www.cms.gov. In the absence of a fee, pricing may reflect the methodolgy used for retail pharmacies. Go to data.medicaid.gov for a complete list of drug NDCs participating in the Medicaid drug rebate program. Consult with each Managed Care Organization (MCO) about their coverage guidelines and prior authroization requirements, if applicable. Highlights represent updated material for each specific revision of the Drug Code List. Code Description Brand Name NDC NDC unit Category Service AC CAH P NP MW MH HS PO OPH HI ID DC Special Instructions req. of Limits OP OP TF for measure drug rebate ? 90281 human ig, im Gamastan Yes ML Antisera NONE X X X X Closed 3/31/13. 90283 human ig, iv Gamimune, Yes ML Antisera NONE X X X X Closed 3/31/13. Cost invoice required with claim. Restricted to ICD-9 diagnoses codes 204.10 - 204.12, Flebogamma, 279.02, 279.04, 279.06, 279.12, 287.31, and 446.1, and must be included on claim form, effective 10/1/09. Gammagard 90287 botulinum antitoxin N/A Antisera Not Covered 90288 botulism ig, iv No ML NONE X X X X Requires documentation and medical review 90291 cmv ig, iv Cytogam Yes ML Antisera NONE X X X X Closed 3/31/13.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Pharmacological Management of Acromegaly: a Current Perspective
    Neurosurg Focus 29 (4):E14, 2010 Pharmacological management of acromegaly: a current perspective SUNIL MANJILA , M.D.,1 Osmo N D C. WU, B.A.,1 FAH D R. KHAN , M.D., M.S.E.,1 ME H ree N M. KHAN , M.D.,2 BAHA M. AR A F AH , M.D.,2 AN D WA rre N R. SE L M AN , M.D.1 1Department of Neurological Surgery, The Neurological Institute, and 2Division of Clinical and Molecular Endocrinology, University Hospitals Case Medical Center, Cleveland, Ohio Acromegaly is a chronic disorder of enhanced growth hormone (GH) secretion and elevated insulin-like growth factor–I (IGF-I) levels, the most frequent cause of which is a pituitary adenoma. Persistently elevated GH and IGF-I levels lead to substantial morbidity and mortality. Treatment goals include complete removal of the tumor causing the disease, symptomatic relief, reduction of multisystem complications, and control of local mass effect. While trans- sphenoidal tumor resection is considered first-line treatment of patients in whom a surgical cure can be expected, pharmacological therapy is playing an increased role in the armamentarium against acromegaly in patients unsuitable for or refusing surgery, after failure of surgical treatment (inadequate resection, cavernous sinus invasion, or transcap- sular intraarachnoid invasion), or in select cases as primary treatment. Three broad drug classes are available for the treatment of acromegaly: somatostatin analogs, dopamine agonists, and GH receptor antagonists. Somatostatin analogs are considered as the first-line pharmacological treatment of acromegaly, although effica- cy varies among the different formulations. Octreotide long-acting release (LAR) appears to be more efficacious than lanreotide sustained release (SR).
    [Show full text]
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16
    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
    [Show full text]
  • To Download a List of Prescription Drugs Requiring Prior Authorization
    Essential Health Benefits Standard Specialty PA and QL List July 2016 The following products require prior authorization. In addition, there may be quantity limits for these drugs, which is notated below. Therapeutic Category Drug Name Quantity Limit Anti-infectives Antiretrovirals, HIV SELZENTRY (maraviroc) None Cardiology Antilipemic JUXTAPID (lomitapide) 1 tab/day PRALUENT (alirocumab) 2 syringes/28 days REPATHA (evolocumab) 3 syringes/28 days Pulmonary Arterial Hypertension ADCIRCA (tadalafil) 2 tabs/day ADEMPAS (riociguat) 3 tabs/day FLOLAN (epoprostenol) None LETAIRIS (ambrisentan) 1 tab/day OPSUMIT (macitentan) 1 tab/day ORENITRAM (treprostinil diolamine) None REMODULIN (treprostinil) None REVATIO (sildenafil) Soln None REVATIO (sildenafil) Tabs 3 tabs/day TRACLEER (bosentan) 2 tabs/day TYVASO (treprostinil) 1 ampule/day UPTRAVI (selexipag) 2 tabs/day UPTRAVI (selexipag) Pack 2 packs/year VELETRI (epoprostenol) None VENTAVIS (iloprost) 9 ampules/day Central Nervous System Anticonvulsants SABRIL (vigabatrin) pack None Depressant XYREM (sodium oxybate) 3 bottles (540 mL)/30 days Neurotoxins BOTOX (onabotulinumtoxinA) None DYSPORT (abobotulinumtoxinA) None MYOBLOC (rimabotulinumtoxinB) None XEOMIN (incobotulinumtoxinA) None Parkinson's APOKYN (apomorphine) 20 cartridges/30 days Sleep Disorder HETLIOZ (tasimelteon) 1 cap/day Dermatology Alkylating Agents VALCHLOR (mechlorethamine) Gel None Electrolyte & Renal Agents Diuretics KEVEYIS (dichlorphenamide) 4 tabs/day Endocrinology & Metabolism Gonadotropins ELIGARD (leuprolide) 22.5 mg
    [Show full text]
  • Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
    International Journal of Molecular Sciences Review Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future Anna Kathrin Stueven 1, Antonin Kayser 1, Christoph Wetz 2, Holger Amthauer 2, Alexander Wree 1, Frank Tacke 1, Bertram Wiedenmann 1, Christoph Roderburg 1,* and Henning Jann 1 1 Charité, Campus Virchow Klinikum and Charité, Campus Mitte, Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] (A.K.S.); [email protected] (A.K.); [email protected] (A.W.); [email protected] (F.T.); [email protected] (B.W.); [email protected] (H.J.) 2 Charité, Campus Virchow Klinikum and Charité, Campus Mitte, Department of Nuclear Medicine, Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] (C.W.); [email protected] (H.A.) * Correspondence: [email protected]; Tel.: +49-30-450-553022 Received: 3 May 2019; Accepted: 19 June 2019; Published: 22 June 2019 Abstract: In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no longer available. Prognosis and survival of patients with NETs are determined by the location of the primary lesion, biochemical functional status, differentiation, initial staging, and response to treatment. Somatostatin analogue (SSA) therapy has been a mainstay of antisecretory therapy in functioning neuroendocrine tumors, which cause various clinical symptoms depending on hormonal hypersecretion. Beyond symptomatic management, recent research demonstrates that SSAs exert antiproliferative effects and inhibit tumor growth via the somatostatin receptor 2 (SSTR2).
    [Show full text]
  • Regulatory Mechanisms of Somatostatin Expression
    International Journal of Molecular Sciences Review Regulatory Mechanisms of Somatostatin Expression Emmanuel Ampofo * , Lisa Nalbach, Michael D. Menger and Matthias W. Laschke Institute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg/Saar, Germany; [email protected] (L.N.); [email protected] (M.D.M.); [email protected] (M.W.L.) * Correspondence: [email protected]; Tel.: +49-6841-162-6561; Fax: +49-6841-162-6553 Received: 25 May 2020; Accepted: 9 June 2020; Published: 11 June 2020 Abstract: Somatostatin is a peptide hormone, which most commonly is produced by endocrine cells and the central nervous system. In mammals, somatostatin originates from pre-prosomatostatin and is processed to a shorter form, i.e., somatostatin-14, and a longer form, i.e., somatostatin-28. The two peptides repress growth hormone secretion and are involved in the regulation of glucagon and insulin synthesis in the pancreas. In recent years, the processing and secretion of somatostatin have been studied intensively. However, little attention has been paid to the regulatory mechanisms that control its expression. This review provides an up-to-date overview of these mechanisms. In particular, it focuses on the role of enhancers and silencers within the promoter region as well as on the binding of modulatory transcription factors to these elements. Moreover, it addresses extracellular factors, which trigger key signaling pathways, leading to an enhanced somatostatin expression in health and disease. Keywords: somatostatin; pre-prosomatostatin; δ-cells; central nervous system (CNS); gut; hypothalamus; cAMP resonse element (CRE); pancreas/duodenum homeobox protein (PDX)1; paired box protein (PAX)6; growth hormone (GH); brain-derived neurotrophic factor (BDNF); glutamateric system; pancreas 1.
    [Show full text]
  • Hypothalamic-Pituitary Axes
    Hypothalamic-Pituitary Axes Hypothalamic Factors Releasing/Inhibiting Pituitary Anterior Pituitary Hormones Circulating ACTH PRL GH Hormones February 11, 2008 LH FSH TSH Posterior Target Pituitary Gland and Hormones Tissue Effects ADH, oxytocin The GH/IGF-I Axis Growth Hormone Somatostatin GHRH Hypothalamus • Synthesized in the anterior lobe of the pituitary gland in somatotroph cells PITUITARY • ~75% of GH in the pituitary and in circulation is Ghrelin 191 amino acid single chain peptide, 2 intra-molecular disulfide bonds GH Weight; 22kD • Amount of GH secreted: IGF-I Women: 500 µg/m2/day Synthesis IGF- I Men: 350 µg/m2/day LIVER Local IGF-I Synthesis CIRCULATION GH Secretion: Primarily Pulsatile Pattern of GH Secretion Regulation by two hypothalamic in a Healthy Adult hormones 25 Sleep 20 Growth - SMS Hormone 15 Somatostatin Releasing GHRH + GH (µg/L) Hormone Inhibitory of 10 Stimulatory of GH Secretion GH Secretion 05 0 GHRH induces GH Somatostatin: Decreases to allow 0900 2100 0900 synthesis and secretion Clocktime GH secretory in somatotrophs Bursts GH From: “Acromegaly” by Alan G. Harris, M.D. 1 Other Physiological Regulators of GH Secretion Pharmacologic Agents Used to Stimulate GH Secretion Amino Sleep Exercise Stress Acids Fasting Glucose Stimulate hypothalamic GHRH or Inhibit Somatostatin Hypothalamus GHRH SMS Hypoglycemia(Insulin) Pituitary L-dopa Arginine Clonidine GHRH + - SMS Pyridostigmine GH Target Tissues Metabolic & Growth Promoting GH Effects IGF-I Insulin-like growth factor I (IGF-I) Major Determinants of Circulating
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
    [Show full text]
  • And Signifor LAR (Pasireotide) Prior Authorization with Quantity Limit
    Signifor (pasireotide) and Signifor LAR (pasireotide) Prior Authorization with Quantity Limit Program Summary Signi for is the only target in this prior authorization program. Signifor LAR is not targeted in this pharmacy prior authorization program. This program applies to Commercial, NetResults A series, SourceRx, and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Signifor (pasireotide) and Signifor LAR Prior Authorization (PA) program is to appropriately select patients for treatment according to product labeling and/or clinical studies and/or clinical practice guidelines. The program will approve for doses within the set limit. Doses above the set limit will be approved if the requested quantity is below the FDA limit and cannot be dose optimized or when the quantity is above the FDA limit and the prescriber has submitted documentation in support of therapy with a higher dose for the intended diagnosis. TARGET DRUGS Signifor (pasireotide) PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Initial Evaluation Signifor will be approved for INITIAL USE when ALL of the following are met: 1. If Signifor, ONE of the following: A. The patient has a diagnosis of Cushing’s disease and ONE of the following: I. The patient has had recurrence or persistence after pituitary surgical resection OR II. The patient is not a candidate for pituitary surgical resection OR B. The patient has another FDA approved diagnosis AND 2. If Signifor LAR, ONE of the following: A. The patient has a diagnosis of acromegaly and ONE of the following: I. The use of requested agent is for adjunctive therapy with irradiation to alleviate acromegaly symptoms OR II.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Role of Androgens, Progestins and Tibolone in the Treatment of Menopausal Symptoms: a Review of the Clinical Evidence
    REVIEW Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence Maria Garefalakis Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well- Martha Hickey established treatment for menopausal symptoms. High quality evidence confi rms that estrogen effectively treats hot fl ushes, night sweats and vaginal dryness. Progestins are combined with School of Women’s and Infants’ Health The University of Western Australia, estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot fl ushes, King Edward Memorial Hospital, but are less effective than estrogen for this purpose. Data are confl icting regarding the role of Subiaco, Western Australia, Australia androgens for improving libido and well-being. The synthetic steroid tibolone is widely used in Europe and Australasia and effectively treats hot fl ushes and vaginal dryness. Tibolone may improve libido more effectively than estrogen containing HT in some women. We summarize the data from studies addressing the effi cacy, benefi ts, and risks of androgens, progestins and tibolone in the treatment of menopausal symptoms. Keywords: androgens, testosterone, progestins, tibolone, menopause, therapeutic Introduction Therapeutic estrogens include conjugated equine estrogens, synthetically derived piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol valerate. Estradiol may also be given transdermally as a patch or gel, as a slow release percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens include topical estradiol in the form of a ring or pessary, estriol in pessary or cream form, dienoestrol and conjugated estrogens in the form of creams. In some countries there is increasing prescribing of a combination of estradiol, estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private compounding pharmacists.
    [Show full text]